Shares of Baxter International Inc (NYSE:BAX) have been assigned an average rating of “Buy” from the sixteen research firms that are presently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $75.62.

Several analysts have issued reports on the stock. Zacks Investment Research lowered shares of Baxter International from a “buy” rating to a “hold” rating in a research report on Thursday, May 31st. JPMorgan Chase & Co. upped their price target on shares of Baxter International from $80.00 to $85.00 and gave the stock an “overweight” rating in a research report on Friday, July 27th. Citigroup upped their price target on shares of Baxter International from $74.00 to $76.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 31st. Bank of America upped their price target on shares of Baxter International from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Tuesday, May 22nd. Finally, Piper Jaffray Companies assumed coverage on shares of Baxter International in a research report on Thursday, May 17th. They set an “overweight” rating and a $77.00 price target on the stock.

In other news, Director Carole J. Shapazian sold 5,400 shares of the stock in a transaction dated Wednesday, August 8th. The shares were sold at an average price of $72.97, for a total value of $394,038.00. Following the transaction, the director now directly owns 15,248 shares of the company’s stock, valued at $1,112,646.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Carole J. Shapazian sold 6,594 shares of the stock in a transaction dated Tuesday, May 22nd. The shares were sold at an average price of $71.79, for a total transaction of $473,383.26. Following the completion of the transaction, the director now directly owns 16,442 shares in the company, valued at $1,180,371.18. The disclosure for this sale can be found here. Insiders sold 94,877 shares of company stock worth $6,880,155 over the last three months. Insiders own 0.07% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. State of Tennessee Treasury Department raised its position in shares of Baxter International by 5.0% in the first quarter. State of Tennessee Treasury Department now owns 437,255 shares of the medical instruments supplier’s stock valued at $28,439,000 after purchasing an additional 20,992 shares during the period. Montag A & Associates Inc. acquired a new position in shares of Baxter International in the second quarter valued at about $816,000. Mn Services Vermogensbeheer B.V. grew its stake in shares of Baxter International by 1.3% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 77,105 shares of the medical instruments supplier’s stock valued at $5,015,000 after acquiring an additional 1,000 shares in the last quarter. MetLife Investment Advisors LLC grew its stake in shares of Baxter International by 92.8% in the first quarter. MetLife Investment Advisors LLC now owns 299,090 shares of the medical instruments supplier’s stock valued at $19,453,000 after acquiring an additional 143,990 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. grew its stake in shares of Baxter International by 13.0% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 3,502,519 shares of the medical instruments supplier’s stock valued at $227,803,000 after acquiring an additional 404,135 shares in the last quarter. 82.92% of the stock is currently owned by institutional investors.

Shares of BAX stock traded down $0.79 during trading on Wednesday, reaching $70.71. The company’s stock had a trading volume of 1,936,300 shares, compared to its average volume of 3,092,013. The company has a quick ratio of 2.03, a current ratio of 2.62 and a debt-to-equity ratio of 0.39. The firm has a market cap of $38.20 billion, a PE ratio of 28.95, a P/E/G ratio of 1.79 and a beta of 0.77. Baxter International has a one year low of $60.06 and a one year high of $76.51.

Baxter International (NYSE:BAX) last posted its quarterly earnings results on Thursday, July 26th. The medical instruments supplier reported $0.77 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.06. Baxter International had a net margin of 8.29% and a return on equity of 16.63%. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.83 billion. During the same period in the prior year, the firm posted $0.63 earnings per share. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. equities analysts predict that Baxter International will post 2.98 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 1st. Stockholders of record on Friday, August 31st will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a dividend yield of 1.07%. The ex-dividend date of this dividend is Thursday, August 30th. Baxter International’s payout ratio is presently 30.65%.

Baxter International Company Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Article: Are Wall Street analysts’ stock ratings worth following?

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.